Hyporesponsiveness to erythropoiesis-stimulating agents and renal survival in non-dialysis CKD patients

Nephrology Dialysis Transplantation

Volumn 27, Issue 7, 2012, Pages 2880-2886

  Minutolo, Roberto ^a,b   Conte, Giuseppe ^a,b   Cianciaruso, Bruno ^c   Bellizzi, Vincenzo ^d   Camocardi, Andrea ^a,b   De Paola, Luigi ^a,b   De Nicola, Luca ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b PO Incurabili ASL NA1   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d University Hospital   (Italy)

Author keywords

Anaemia; CKD; erythropoietin; ESA responsiveness; ESRD

Indexed keywords

ANTIANEMIC AGENT; ANTIHYPERTENSIVE AGENT; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OUTPATIENT; PATIENT CODING; PRIORITY JOURNAL; PROGNOSIS; PROTEINURIA; SURVIVAL; TREATMENT DURATION;

AGED; CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DIABETES MELLITUS; ERYTHROPOIESIS; FEMALE; FOLLOW-UP STUDIES; HEMATINICS; HEMOGLOBINS; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; RENAL DIALYSIS; SURVIVAL RATE;

EID: 84864398621     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs007     Document Type: Article

References (39)

1. Zhang Y, Thamer M, Stefanik K et al. Epoetin requirements predict mortality in hemodialysis patients. Am J Kidney Dis 2004; 44: 866-876.
2. Kaysen GA, Müller HG, Ding J et al. Challenging the validity of the EPO index. Am J Kidney Dis 2006; 47: 157-166.
3. Kilpatrick R, Critchlow C, Fishbane S et al. Greater epoetin alfa responsiveness is associated with improved survival in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3: 1077-1083.
4. López-Gómez J, Portolés J, Aljama P. Factors that condition the response to erythropoietin in patients on hemodialysis and their relation to mortality. Kidney Int 2008; 74Suppl 111S75-S81.
5. Panichi V, Rosati A, Bigazzi R et al. Anaemia and resistance to erythropoiesis-stimulating agents as prognostic factors in haemodialysis patients: results from the RISCAVID study. Nephrol Dial Transplant 2011; 26: 2641-2648.
6. Fukuma S, Yamaguchi T, Hashimoto S et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the dialysis registry in Japan. Am J Kidney Dis 2011; 59: 108-116.
7. Besarab B, Yee J. Candidate biomarkers for erythropoietin response in end-stage renal disease. Kidney Int 2011; 79: 488-490.
8. Rossert J, Gassmann-Mayer C, Frei D et al. Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. Nephrol Dial Transplant 2007; 22: 794-800.
9. Solomon SD, Uno H, Lewis EF et al. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010; 363: 1146-1155.
10. Locatelli F, Del Vecchio L. Erythropoietic response to erythropoiesis-stimulating agents and outcome: should we give up the haemoglobin target approach?. Nephrol Dial Transplant 2011; 6: 2069-2071.
11. De Nicola L, Chiodini P, Zoccali C et al. Prognosis of CKD patients receiving outpatient nephrology care in Italy. Clin J Am Soc Nephrol 2011; 6: 2421-2428.
12. Minutolo R, Zamboli P, Chiodini P et al. Conversion of darbepoetin to low doses of CERA maintains hemoglobin levels in non-dialysis chronic kidney disease patients. Blood Purif 2010; 30: 186-194.
13. Drüeke TB, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
14. Cianciaruso B, Ravani P, Barrett BJ et al. Italian randomized trial of hemoglobin maintenance to prevent or delay left ventricular hypertrophy in chronic kidney disease. J Nephrol 2008; 21: 861-870.
15. Macdougall IC, Temple MR et al. Is early treatment of anaemia with epoetin-α beneficial to pre-dialysis chronic kidney disease patients? Results of a multicentre, open-label, prospective, randomized, comparative group trial. Nephrol Dial Transplant 2007; 22: 784-793.
16. Gouva C, Nikolopoulos P, Ioannidis JP et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-760.
17. Ritz E, Laville M, Bilous RWet al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the anemia correction in diabetes (ACORD) Study. Am J Kidney Dis 2007; 49: 194-207.
18. Furuland H, Linde T, Ahlmen J et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. Nephrol Dial Transplant 2003; 18: 353-361.
19. Obi Y, Kimura T, Nagasawa Y et al. Impact of age and overt proteinuria on outcomes of stage 3 to 5 chronic kidney disease in a referred cohort. Clin J Am Soc Nephrol 2010; 9: 1558-1565.
20. Landray MJ, Emberson JR, Blackwell L et al. Prediction of ESRD and death among people with CKD: the Chronic Renal Impairment in Birmingham (CRIB) prospective cohort study. Am J Kidney Dis 2010; 56: 1082-1094.
21. Di Iorio BR, Minutolo R, De Nicola L et al. Supplemented very low protein diet ameliorates responsiveness to erythropoietin in chronic renal failure. Kidney Int 2003; 64: 1822-1828.
22. Szczech LA, Barnhart HX, Inrig JK et al. Secondary analysis of the CHOIR trial epoetin-a dose and achieved hemoglobin outcomes. Kidney Int 2008; 74: 791-798.
23. Rossert J, Levin A, Roger SD et al. Effect of early correction of anemia on the progression of chronic kidney disease. Am J Kidney Dis 2006; 47: 738-750.
24. Levin A, Djurdjev O, Thompson C et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005; 46: 799-811.
25. McFarlane PA, Pisoni RL, Eichleay MA et al. International trends in erythropoietin use and hemoglobin levels in hemodialysis patients. Kidney Int 2010; 78: 215-223.
26. De Nicola L, Conte G, Chiodini P et al. Stability of target hemoglobin levels during the first year of epoetin treatment in CKD patients. Clin J Am Soc Nephrol 2007; 2: 938-946.
27. Minutolo R, Chiodini P, Cianciaruso B et al. Epoetin therapy and hemoglobin level variability in non-dialysis CKD patients. Clin J Am Soc Nephrol 2009; 4: 552-559.
28. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008; 74: 867-872.
29. Norman JT, Clark IM, Garcia PL. Hypoxia promotes fibrogenesis in human renal fibroblasts. Kidney Int 2000; 58: 2351-2366.
30. Norman JT, Fine LG. Intrarenal oxygenation in chronic renal failure. Clin Exp Pharmacol Physiol 2006; 33: 989-996.
31. Elliott J, Mishler D, Agarwal R. Hyporesponsiveness to erythropoietin: causes and management. Adv Chronic Kidney Dis 2009; 16: 94-100.
32. Kalantar-Zadeh K, McAllister CJ, Lehn RS et al. Effect of malnutrition-inflammation complex syndrome on EPO hyporesponsiveness in maintenance hemodialysis patients. Am J Kidney Dis 2003; 42: 761-773.
33. Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med 1993; 328: 171-175.
34. Bosman DR, Winkler AS, Marsden JT et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 2001; 24: 495-499.
35. Thomas MC, Cooper ME, Tsalamandris C et al. Anemia with impaired erythropoietin response in diabetic patients. Arch Intern Med 2005; 165: 466-469.
36. Sasso FC, De Nicola L, Carbonara O et al. Cardiovascular risk factors and disease management in type 2 diabetic patients with diabetic nephropathy. Diabetes Care 2006; 29: 498-503.
37. Fehr T, Ammann P, Garzoni D et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int 2004; 66: 1206-1211.
38. Gilbertson DT, Ebben JP, Foley RN et al. Hemoglobin level variability: associations with mortality. Clin J Am Soc Nephrol 2008; 3: 133-138.
39. Boudville NC, Djurdjev O, Macdougall IC et al. Hemoglobin variability in nondialysis chronic kidney disease: examining the association with mortality. Clin J Am Soc Nephrol 2009; 4: 1176-1182.